Published in Endocrinology on January 01, 2001
Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesis. Proc Natl Acad Sci U S A (2007) 1.00
Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism. Cancer Biol Ther (2011) 0.94
Interruption of growth hormone signaling via SHC and ERK in 3T3-F442A preadipocytes upon knockdown of insulin receptor substrate-1. Mol Endocrinol (2009) 0.84
The GH/IGF-1 Axis and Heart Failure. Curr Cardiol Rev (2009) 0.84
Effect of the combination of fibrin glue and growth hormone on intestinal anastomoses in a pig model of traumatic shock associated with peritonitis. World J Surg (2009) 0.82
Modulation of growth hormone receptor abundance and function: roles for the ubiquitin-proteasome system. Biochim Biophys Acta (2008) 0.80
Potentiation of tumour apoptosis by human growth hormone via glutathione production and decreased NF-kappaB activity. Br J Cancer (2003) 0.77
Cell-cycle control of c-myc but not c-ras expression is lost following chemical transformation. Cell (1984) 6.53
Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest (1997) 3.96
Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev (1998) 3.82
Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev (1997) 3.12
Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J (1996) 2.68
Laron dwarfism and mutations of the growth hormone-receptor gene. N Engl J Med (1989) 2.45
Interaction of an NF-kappa B-like factor with a site upstream of the c-myc promoter. Proc Natl Acad Sci U S A (1990) 2.06
Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene (2001) 2.05
Dual expression of lambda genes in the MOPC-315 plasmacytoma. Nature (1981) 2.03
Cloning and expression of the rat prolactin receptor, a member of the growth hormone/prolactin receptor gene family. Cell (1988) 2.00
Regulation of c-myc transcription and mRNA abundance by serum growth factors and cell contact. J Biol Chem (1986) 2.00
Are younger classroom children disproportionately referred for childhood academic and behavior problems? J Consult Clin Psychol (1987) 1.99
Protein kinase CK2 in mammary gland tumorigenesis. Oncogene (2001) 1.90
LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med (1990) 1.83
TGF beta 1 inhibits NF-kappa B/Rel activity inducing apoptosis of B cells: transcriptional activation of I kappa B alpha. Immunity (1996) 1.81
Studies of insulin, growth hormone and prolactin binding: tissue distribution, species variation and characterization. Endocrinology (1974) 1.81
Specific regulation of c-myc oncogene expression in a murine B-cell lymphoma. Proc Natl Acad Sci U S A (1984) 1.76
Prolactin controls mammary gland development via direct and indirect mechanisms. Dev Biol (1999) 1.70
Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors. Mol Cell Biol (1994) 1.68
Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects. Dev Biol (2001) 1.66
The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene (2000) 1.66
Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene (2001) 1.59
Independent regulation of transcription of the two strands of the c-myc gene. Mol Cell Biol (1987) 1.58
Radioreceptor assay for prolactin and other lactogenic hormones. Science (1973) 1.56
Transactivation of the c-myc promoter by human T cell leukemia virus type 1 tax is mediated by NF kappa B. J Biol Chem (1992) 1.56
Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest (2000) 1.54
The prolactin/growth hormone receptor family. Endocr Rev (1991) 1.53
Transcriptional activation of immunoglobulin alpha heavy-chain genes by translocation of the c-myc oncogene. Nature (1983) 1.51
Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NF-kappaB signaling: linking development and cancer. Cell Mol Life Sci (2009) 1.50
A homozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein. J Clin Endocrinol Metab (1996) 1.49
Identification of a cDNA encoding a long form of prolactin receptor in human hepatoma and breast cancer cells. Mol Endocrinol (1989) 1.48
Readability of pediatric biomedical research informed consent forms. Pediatrics (1990) 1.43
Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer. Cancer Res (2001) 1.43
Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci U S A (1992) 1.42
Balancing the risks and benefits of genomic data sharing: genome research participants' perspectives. Public Health Genomics (2011) 1.40
JAK2 activation and cell proliferation induced by antibody-mediated prolactin receptor dimerization. Endocrinology (1994) 1.40
Comparison of long and short forms of the prolactin receptor on prolactin-induced milk protein gene transcription. Proc Natl Acad Sci U S A (1991) 1.40
Ciprofloxacin does not block the antiproliferative effect of tacrolimus. Transplantation (1997) 1.39
Intracellular association of the protein product of the c-myc oncogene with the TATA-binding protein. Mol Cell Biol (1994) 1.39
Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals. Endocr Rev (1996) 1.38
Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary cells. Carcinogenesis (2000) 1.38
Nuclear factor-kappaB/Rel blocks transforming growth factor beta1-induced apoptosis of murine hepatocyte cell lines. Cell Growth Differ (1997) 1.36
Expression of a constitutive NF-kappa B-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. J Clin Invest (1995) 1.36
Prolactin receptor triggering. Evidence for rapid tyrosine kinase activation. J Biol Chem (1992) 1.35
Disproportionate referrals for child academic/behavior problems: replication and extension. J Consult Clin Psychol (1990) 1.35
Role of Rel-related factors in control of c-myc gene transcription in receptor-mediated apoptosis of the murine B cell WEHI 231 line. J Exp Med (1995) 1.35
Studies of insulin, growth hormone and prolactin binding: ontogenesis, effects of sex and pregnancy. Endocrinology (1974) 1.35
Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia (2007) 1.33
Transcriptional and posttranscriptional control of c-myc gene expression in WEHI 231 cells. Mol Cell Biol (1986) 1.32
Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab (1998) 1.31
The utility of the Kohlman Evaluation of Living Skills test is associated with substantiated cases of elder self-neglect. J Am Acad Nurse Pract (2007) 1.29
Structural symmetry of the extracellular domain of the cytokine/growth hormone/prolactin receptor family and interferon receptors revealed by hydrophobic cluster analysis. FEBS Lett (1991) 1.28
Expression of prolactin and its receptor in human lymphoid cells. Mol Endocrinol (1992) 1.27
Null mutation of the prolactin receptor gene produces a defect in maternal behavior. Endocrinology (1998) 1.27
Identification and sequence analysis of a second form of prolactin receptor by molecular cloning of complementary DNA from rabbit mammary gland. Proc Natl Acad Sci U S A (1989) 1.26
Perivascular microapplication of endothelin-1: a new model of focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab (1993) 1.25
Regulation of oncogene expression in cultured aortic smooth muscle cells. Post-transcriptional control of c-myc mRNA. J Biol Chem (1986) 1.23
Distinct cytoplasmic regions of the growth hormone receptor are required for activation of JAK2, mitogen-activated protein kinase, and transcription. Endocrinology (1994) 1.23
Mammary gland development in prolactin receptor knockout mice. J Mammary Gland Biol Neoplasia (1997) 1.23
Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling. J Biol Chem (1999) 1.22
Transcription of immunoglobulin heavy-chain sequences from the excluded allele. Nature (1981) 1.21
Role of the IkappaB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells. Mol Cell Biol (2000) 1.21
Evolution of prolactin receptors in rabbit mammary gland during pregnancy and lactation. Endocrinology (1977) 1.21
Induction of a lactogenic receptor in rat liver: influence of estrogen and the pituitary. Proc Natl Acad Sci U S A (1974) 1.18
Proline-rich sequence-mediated Jak2 association to the prolactin receptor is required but not sufficient for signal transduction. J Biol Chem (1995) 1.18
Inhibition of NF-kappa B activity induces apoptosis in murine hepatocytes. Am J Pathol (1997) 1.18
Expression of two forms of prolactin receptor in rat ovary and liver. Mol Endocrinol (1990) 1.17
Prolactin-induced proliferation of Nb2 cells involves tyrosine phosphorylation of the prolactin receptor and its associated tyrosine kinase JAK2. J Biol Chem (1994) 1.17
Prolactin receptors in rat liver: possible induction by prolactin. Science (1975) 1.15
Inhibition of c-myc expression induces apoptosis of WEHI 231 murine B cells. Mol Cell Biol (1996) 1.15
Activation of JAK2 tyrosine kinase by prolactin receptors in Nb2 cells and mouse mammary gland explants. Proc Natl Acad Sci U S A (1994) 1.14
Green tea extracts decrease carcinogen-induced mammary tumor burden in rats and rate of breast cancer cell proliferation in culture. J Cell Biochem (2001) 1.14
Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle. J Biol Chem (1989) 1.13
Characteristics and polyadenylate content of the actin messenger RNA of mouse sarcoma-180 ascites cells. Biochemistry (1978) 1.13
The inhibitory effects of transforming growth factor beta1 on breast cancer cell proliferation are mediated through regulation of aberrant nuclear factor-kappaB/Rel expression. Cell Growth Differ (1999) 1.12
Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling. Oncogene (2009) 1.12
Maintenance of nuclear factor-kappa B/Rel and c-myc expression during CD40 ligand rescue of WEHI 231 early B cells from receptor-mediated apoptosis through modulation of I kappa B proteins. J Immunol (1996) 1.11
Protein kinase CK2: signaling and tumorigenesis in the mammary gland. Mol Cell Biochem (2001) 1.11
Immune system development and function in prolactin receptor-deficient mice. J Immunol (1999) 1.10
NF-kappa B-like factors mediate interleukin 1 induction of c-myc gene transcription in fibroblasts. J Exp Med (1992) 1.10
Regional changes in brain glucose metabolism reflect cognitive impairments in aged rats. J Neurosci (1984) 1.10
Differential translation of mouse myeloma messenger RNAs in a wheat germ cell-free system. Biochemistry (1976) 1.10
Time of synthesis for ribosomal ribonucleic acid in Physarum. Biochemistry (1973) 1.09
Significant differences in charge times among currently available implantable cardioverter defibrillators. Pacing Clin Electrophysiol (1999) 1.08
Multiple expression of Ig lambda-chain encoding RNA species in murine plasmacytoma cells. J Immunol (1981) 1.07
Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J Clin Endocrinol Metab (1997) 1.07
Expression of prolactin and growth hormone receptor genes and their isoforms in the gastrointestinal tract. Am J Physiol (1995) 1.06
Leptin binding activity changes with age: the link between leptin and puberty. J Clin Endocrinol Metab (1999) 1.06
Phosphorylation by the protein kinase CK2 promotes calpain-mediated degradation of IkappaBalpha. J Immunol (2001) 1.05
Expression of the c-myb proto-oncogene in bovine vascular smooth muscle cells. J Biol Chem (1992) 1.05
Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett (1999) 1.05
Insulin-like growth factor-I regulates transcription of the elastin gene. J Biol Chem (1993) 1.05
A prolactin-dependent immune cell line (Nb2) expresses a mutant form of prolactin receptor. J Biol Chem (1991) 1.05
Generation of human soluble leptin receptor by proteolytic cleavage of membrane-anchored receptors. Endocrinology (2001) 1.04
Tissue distribution and regulation of rat prolactin receptor gene expression. Quantitative analysis by polymerase chain reaction. J Biol Chem (1994) 1.04
Expression of the aryl hydrocarbon receptor/transcription factor (AhR) and AhR-regulated CYP1 gene transcripts in a rat model of mammary tumorigenesis. Breast Cancer Res Treat (2000) 1.04
Mutational analysis of the ligand-binding domain of the prolactin receptor. J Biol Chem (1991) 1.04
PTP1D is a positive regulator of the prolactin signal leading to beta-casein promoter activation. EMBO J (1996) 1.02